Jose ignacio Arias Fernandez, He is Doctor in Veterinary Medicine from de University of Chile (2002), Diplomate in veterinary surgery and radiology (2003), and PhD in veterinary science (2008). Is an Assistance Professor in the department of Clinical Science of the School of Veterinary Medicine in the University of Chile since 2011, working as director of the Laboratory of Biomedicine a Regenerative Medicine (BiMre). Member of the Tissue Engineering and Regenerative Medicine International Society (TERMIS), and the "Chilean Society of Veterinary Orthopaedics and Traumatology" (SOCHITOV) as well as being the Chilean representative of the "Latin American Society of Artificial Organs, Biomaterials and Tissue Engineering" (SLABO). The line of work as aimed to bone regeneration and inhibition in traumatology and skin wound healing.
Jose Ignacio Arias Fernandez
Laboratorio de Biomedicina y Medicina Regenerativa, Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile.
It is well documented that the protein Calreticulin is a protein that overexpresses in various events of cellular stress. In the case of skin wounds, this protein is involved in increased migration and cell proliferation along with increased synthesis of collagen and fibrin. We have established, in previous studies, that Trypanosoma cruzi calreticulin (TcCRT) is 2500 times more efficient than its human counterpart in these functions. We have recently studied in which part of the protein were housed the cell migration and proliferation modulation functions that are two fundamental parts of wound repair. After in vitro testing with cell cultures and in vivo tests on healthy and diabetic rats, these functions can be said to be housed in different domains of the protein. This has important implications since flaws in wound healing are as diverse as the complexity of the natural repair process. TcCRT can be a good alternative because it is required in a very low concentration (20ng / μl) in vitro and in vivo to generate its effect. On the other hand, if the wound histologically requires increased cell proliferation or cell migration specific domains may be occupied to stimulate that wound activity. The TcCRT concentrations used in this project are extremely insignificant to commercially approved FDA-produced platelet derived growth factor (PDGF) treatments; Called Regranex®. This growth factor has a cost of $ 1,000 for 15 g of gel with a high concentration of 0.1 mg / ml of PDGF. The results obtained in diabetic wounds allow us to visualize that in the future stimulating cicatrization of chronic wounds with this protein, at a more reasonable cost than the present ones, could be an aide to a nursing management in hospital and at home. We have also found that TcCRT promotes the differentiation of adipose tissue derived stem cells into fibroblastic lineages, potentially increasing their concentration at the wound site. In conclusion, the use of this protein and / or its domains, coupled with stem cell therapy could be a reasonable and plausible alternative in the near future.